Palomino-Bautista Carlos, Sánchez-Jean Rubén, Carmona Gonzalez David, Romero Domínguez Marta, Castillo Gómez Alfredo
Department of Ophthalmology, University Hospital Quirónsalud Madrid, Madrid, Spain.
European University of Madrid, Madrid, Spain.
Clin Ophthalmol. 2020 Apr 9;14:1043-1054. doi: 10.2147/OPTH.S238553. eCollection 2020.
To evaluate the refractive and functional outcomes of the trifocal 1stQ AddOn (Medicontur) supplementary intraocular lenses (IOLs) designed for implantation into the ciliary sulcus.
The study included 18 eyes of 11 pseudophakic patients with uncomplicated previous implantation of monofocal capsular bag IOLs. These patients had a desire for spectacle independence. Distance, intermediate and near visual acuities were measured, and defocus curves were plotted over a period of 6 months following implantation of the add-on IOLs. Intraocular pressure (IOP), endothelial cell density measurements and biomicroscopic evaluation were also performed.
In this study, 83.3% of eyes had spherical refractions within ±0.5 D from emetropia and 100% of eyes had spherical equivalent refractions that were within ±1.0 D of the target refraction. Visual acuities and defocus curves clearly confirmed trifocal optical performance (UDVA=0.03 ±0.05; UIVA=0.21 ±0.04; UNVA=0.12 ±0.04 logMAR; expressed as mean ±SD). Depth of focus showed identical results (DOF=0.486 D) compared to a trifocal capsular bag IOL, while the defocus curve was found to be superior in the intermediate and near ranges when compared to a trifocal capsular bag IOL. All patients achieved spectacle independence at all distances. All add-on IOLs were well positioned in the ciliary sulcus. No negative changes were noted in connection with endothelial cell counts, IOPs, the angle structure during surgery and during the follow-up period.
The supplementary trifocal add-on IOL seems to be a safe, efficient and stable solution for achieving spectacle independence in pseudophakic patients with monofocal primary IOLs.
评估设计用于植入睫状沟的三焦点1stQ AddOn（Medicontur）补充人工晶状体（IOL）的屈光和功能结果。
该研究纳入了11例曾植入单焦点囊袋内IOL且无并发症的假晶状体患者的18只眼。这些患者希望摆脱眼镜。测量了远、中、近视力，并在植入补充IOL后的6个月内绘制了散焦曲线。还进行了眼压（IOP）、内皮细胞密度测量和生物显微镜评估。
在本研究中，83.3%的眼睛球镜屈光度在正视眼±0.5 D范围内，100%的眼睛等效球镜屈光度在目标屈光度±1.0 D范围内。视力和散焦曲线明确证实了三焦点光学性能（UDVA = 0.03±0.05；UIVA = 0.21±0.04；UNVA = 0.12±0.04 logMAR；表示为平均值±标准差）。与三焦点囊袋内IOL相比，焦深显示出相同的结果（DOF = 0.486 D），而与三焦点囊袋内IOL相比，散焦曲线在中距离和近距离范围内更优。所有患者在所有距离均实现了摆脱眼镜。所有补充IOL均在睫状沟内位置良好。在手术期间和随访期间，未观察到与内皮细胞计数、眼压、房角结构相关的负面变化。
对于植入单焦点原发性IOL的假晶状体患者，补充性三焦点IOL似乎是实现摆脱眼镜的安全、有效且稳定的解决方案。
